A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (A...

Full description

Bibliographic Details
Main Authors: Naoto Saito, Takeshi Hatanaka, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga, Kenji Kashiwabara, Norio Kubo, Yasuo Hosouchi, Hiroki Tojima, Satoru Kakizaki, Toshio Uraoka
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Clinical Case Reports
Subjects:
anti‐programmed death ligand‐1
hepatic resection
immune checkpoint inhibitor
liver cancer
vascular endothelial growth factor
Online Access:https://doi.org/10.1002/ccr3.6129

Internet

https://doi.org/10.1002/ccr3.6129

Similar Items